Birnavirus Monotherapy for Nidovirus Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for nidovirus infections, such as COVID-19, lack effective, inexpensive, easily administered, and stable treatment solutions, with existing antiviral drugs showing limited efficacy and safety concerns.
Innovation Solution
The use of attenuated live avian Infectious Bursal Disease Virus (IBDV) from the Birnaviridae family, which activates the interferon-dependent antiviral gene program, is proposed as a treatment for nidovirus infections, including COVID-19, either as a monotherapy or in combination with other active agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antiviral drugs are used for nidovirus infections, then treatment is provided, but efficacy is limited and safety concerns arise
Solution Approach 1:
The invention uses a combination therapy approach, segmenting the treatment into multiple components: birnavirus (to activate interferon response) combined with other antiviral agents. This segmentation allows each component to address different aspects of the viral infection while reducing the burden and side effects on the patient.
Solution Approach 2:
The birnavirus acts as an intermediary that triggers the host's own interferon-dependent antiviral gene program. Rather than directly attacking the nidovirus with potentially harmful chemicals, the birnavirus mediates the activation of the body's natural defense mechanisms, reducing direct drug-toxicity while maintaining efficacy.
2Reliability
If conventional therapies are used for nidovirus infections, then treatment is provided, but the treatment is not inexpensive, easy to administer, or stable
Solution Approach 1:
The birnavirus-based therapy has universal applicability across different nidovirus infections (including SARS-CoV-2, MERS-CoV, SARS-CoV). The mechanism of activating interferon response is a fundamental antiviral pathway that works against multiple virus types, simplifying treatment protocols and making the therapy broadly applicable without needing virus-specific customization.
Solution Approach 2:
The therapy leverages the patient's own immune system to fight the infection. By activating the interferon-dependent antiviral gene program, the treatment makes the body's defense mechanisms work for itself, reducing the need for continuous medical intervention, monitoring, and complex administration protocols.
3Reliability
If higher doses of birnavirus are administered, then therapeutic efficacy increases, but the complexity of dosage management increases
Solution Approach 1:
The invention specifies optimal dosage ranges (10^6 to 10^9 infectious units) that balance efficacy with safety and simplicity. By establishing clear dosage parameters based on the viral load and disease severity, the treatment simplifies dosage management while maintaining therapeutic effectiveness across different patient populations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of IBDV has been shown to be therapeutically effective and safe, with doses of 10^6 to 10^9 infectious units demonstrating efficacy in treating nidovirus infections, including COVID-19, by inducing an antiviral response and reducing symptoms without significant side effects.
Implementation Method 1
the present inventors surprisingly found that viruses of the Birnaviridae family promote activation of the interferon-dependent antiviral gene program
Data Source
AI summary
The present invention relates to a birnavirus for use in the treatment of a disease caused by a nidovirus. Further, the present invention relates to a combination comprising at least one birnavirus and at least one further active agent for use in the treatment of a disease caused by a nidovirus. Furthermore, the present invention relates to a pharmaceutical composition comprising the birnavirus or the combination for use in the treatment of a disease caused by a nidovirus.